The Patent Finder

Methods of Treating Cancer with ANTI-PD-1 Antibodies

Tesaro, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/US2018/013029, filed Jan 9, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,415,855Methods of Treating Cancer with ANTI-PD-1 Antibodies
In force
 · High confidence
Tesaro, Inc.In force
High confidence
US 11,407,830Methods of Treating Cancer with ANTI-PD-1 Antibodies
In force
 · High confidence
Tesaro, Inc.In force
High confidence
Application 19/304,196Methods of Treating Cancer with ANTI-PD-1 Antibodies
Pending
Not granted
Tesaro, Inc.PendingNot granted
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Tesaro, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited